FORM 1449* INFORMATION DISCLOSURE STATEMENT	Docket Number: 10682.0010USWO	Application Number: 10/560,790			
OIPE IN AN APPLICATION	Applicant: Peter GHOSH				
Suse several sheets if necessary)	Filing Date: December 15,	Group Art Unit: Unknown			

TE FEBRUSE	MARK		U.S. PATENT DOCUME	NTS					
EXAMINER INITIAL	DOCUMENT NO	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE			
/KCC/	5,925,736	07/1999	Neff et al.						
		FO	REIGN PATENT DOCUM	MENTS					
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION			
						YES	NO		
/KCC/	WO 03/062279	07/2003	WIPO						
/KCC/	WO 01/93833	12/2001	WIPO						
/KCC/	WO 01/93831	12/2001	WIPO						
	ОТН	R DOCUMENT	S (Including Author, Title,	Date, Pertinent F	Pages, Etc.)				
/KCC/	Type IX	Lu et al., "Different Therapeutic and Bystander Effects by Intranasal Administration of Homologous Type II and Type IX Collagens on the Collagen-Induced Arthritis and Pristane-Induced Arthritis in Rats", Clinical Immunology (1999); 90(1): 119-127							
/KCC/	Myers of Arthriti	Myers et al., "Immunogenicity of Recombinant Type IX Collagen in Murine Collagen-Induced Arthritis", Arthritis & Rheumatism (2002); 46(4): 1086-1093							
/KCC/	Vasios Encode	Vasios et al., "Cartilage Type IX Collagen-Proteoglycan Contains a Large Amino-terminal Globular Domain Encoded by Multiple Exons", The Journal of Biological Chemistry (1988); 263(5): 2324-2329							

23552
PATENT TRADEMARK OFFICE

EXAMINER /Karen Cochrane Carlson/ (12/11/2008) DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.